|
Compound class:
Antibody
Comment: MM-151 is a mixture of three fully human IgG1 monoclonal antibodies, each of which targets a distinct (and nonoverlapping) epitope on the extra-cellular domain of the EGFR [2]. This can be termed an oligoclonal agent. It was designed to target EGFRs with treatment-induced (acquired) resistance mutations that develop in cancer patients treated with the approved anti-EGFR monoclonals cetuximab or panitumumab. Development of the three antibody components is reported in [1].
|
| No information available. |
Summary of Clinical Use  |
| A Phase 1 safety study of MM-151 in patients with advanced, treatment resistant solid tumours has been completed (NCT01520389). A further Phase 1 trial (NCT02538627) is evaluating MM-151 in combination with the ERBB3 (HER3) candidate drug seribantumab (MM-121). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | Phase 1 Interventional | Merrimack Pharmaceuticals | ||
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Phase 1 Interventional | Merrimack Pharmaceuticals | ||
